SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

NCT05436639 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Autonomous Cortisol Secretion (ACS)
ACTH-Independent Cushing Syndrome
ACTH-Independent Adrenal Cushing Syndrome, Somatic

Interventions

DRUG: SPI-62 dose

Sponsor

Sparrow Pharmaceuticals